Our previous study has recently shown that plasma heme oxygenase-1 (HO-1), a stress-responsive protein, is elevated in individuals with type 2 diabetes. The current study aimed to examine the association between plasma HO-1 concentration and impaired glucose regulation (IGR) in non-diabetic individuals.
We conducted a case-control study including a total of 865 subjects (262 IGR individuals and 603 healthy controls) in a Chinese population. Basic characteristics were collected by questionnaire and standardized anthropometric measurements. Plasma HO-1 concentration was determined by ELISA.
Plasma HO-1 concentration was significantly increased in IGR individuals compared with healthy controls (1.34 (0.81–2.29) ng/ml vs 0.98 (0.56–1.55) ng/ml, P<0.001). After adjustment for age, sex, and BMI, the ORs for IGR in the highest quartile of plasma HO-1 concentrations, compared with the lowest, was 3.42 (95% CI 2.11–5.54; P for trend <0.001). The trend remained significant even after additional adjustment for smoking, alcohol drinking, hypertension, family history of diabetes, lipid profiles and C-reactive protein. In the receiver-operating characteristic curve analysis, addition of plasma HO-1 concentration to a model with known risk factors yielded significantly improved discriminative value for IGR (area under the curves 0.75 (95% CI 0.71–0.78) vs. 0.72 (95% CI 0.69–0.76); P for difference = 0.026).
Elevated plasma HO-1 concentration is significantly associated with increased ORs for IGR. However, its clinical utility should be validated in further studies, especially in prospective cohort studies.
Citation: Bao W, Rong S, Zhang M, Yu X, Zhao Y, et al. (2012) Plasma Heme Oxygenase-1 Concentration in Relation to Impaired Glucose Regulation in a Non-Diabetic Chinese Population. PLoS ONE 7(3): e32223. doi:10.1371/journal.pone.0032223
Editor: German Malaga, Universidad Peruana Cayetano Heredia, Peru
Received: November 12, 2011; Accepted: January 23, 2012; Published: March 12, 2012
Copyright: © 2012 Bao et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by National Natural Science Foundation (NSFC-30872116) and National High Technology Research and Development Program (863 Program, 2009AA022704) of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Individuals with impaired glucose regulation (IGR), including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), has been demonstrated to exert relatively high risk for the future development of type 2 diabetes mellitus (T2DM)  as well as cardiovascular disease (CVD) . Although the pathogenesis of IGR remains unclear, enhanced oxidative stress in the form of lipid peroxidation and DNA oxidative damage in IGR is found in previous studies , . In fact, oxidative stress has been implicated in insulin resistance and beta-cell dysfunction which are essential clinical characteristics of IGR and T2DM . Heme oxygenase-1 (HMOX1 or HO-1), also termed as heat shock protein 32, is the inducible isoform of heme oxygenase that catalyzes the NADPH-dependent decomposition of heme to carbon monoxide (CO), ferrous iron, and biliverdin . HO-1 expression is highly responsive to a broad spectrum of chemical and physical stress agents, such as hydrogen peroxide, heavy metals, UVA irradiation, hypoxia, hyperoxia, pro-inflammatory cytokines and heme itself , . Therefore, HO-1 as a stress-inducible protein has been suggested to be a sensitive and reliable marker of oxidative stress status , .
Recently, we have reported that plasma level of HO-1 is significantly elevated in T2DM patients compared with non-diabetic controls (including IGR individuals and healthy controls) . In addition, we have found that plasma HO-1 levels are significantly correlated with plasma glucose concentrations (FPG and OGTT2h), HOMA-beta, and HOMA-IR , which makes us think whether plasma HO-1 levels are significantly increased in non-diabetic individuals with moderate hyperglycemia but under the cut-point of diabetes diagnosis. Similar elevation of circulating HO-1 levels has also been found in CVD ,  and other chronic diseases , , . However, the association between plasma HO-1 concentration and IGR has not yet been investigated.
Thus, in this study, we aimed to assess the association between plasma HO-1 concentration and IGR without or with adjustment for known risk factors for IGR. Additionally, we compared the discriminative value of models for IGR without or with plasma HO-1.
A total of 865 participants, including 262 IGR individuals and 603 healthy controls, were recruited for the current study. Some of these participants are included in our previous study  as non-diabetic controls. IGR individuals were consecutively recruited from those attending the outpatient clinics of Department of Endocrinology of Tongji Hospital affiliated to Tongji Medical College during the period of December 2004 to December 2007. Healthy controls were drawn from an unselected group of population that underwent for a routine health examination in the same hospital during the same period. IGR, including impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), was diagnosed in accordance with the criteria recommended by World Health Organization in 2006 incorporating both fasting plasma glucose (FPG) and a 2-h oral glucose tolerance test (OGTT) . IFG was defined as 6.1 mmol/L≤FPG<7.0 mmol/L and OGTT2h<7.8 mmol/L; IGT was defined as FPG<7.0 mmol/L and 7.8 mmol/L≤OGTT2h<11.1 mmol/L; and healthy control was defined as FPG<6.1 mmol/L and OGTT2h<7.8 mmol/L. For both the IGR cases and controls, we restricted the study subjects to only individuals who were aged ≥30 years, BMI<40 kg/m2, no early history of diagnosed diabetes, nor any other clinically systemic diseases, acute or chronic inflammatory diseases, acute respiratory infection, known cardiovascular disease or cancer. The study protocol was approved by Medical Ethics Committee of Tongji Medical College according to the declaration of Helsinki and written informed consent was obtained from all individuals.
As previously described , , information about age, sex, smoking, alcohol drinking, hypertension, and family history of diabetes in their first-degree relatives were collected by questionnaire survey. Anthropometric measurements including height (m), weight (kg) and blood pressure (mmHg) were performed using standardized techniques. Body mass index (BMI) was calculated as weight (kg)/square of height (m2).
Antecubital venous blood samples were drawn into heparinized tubes from all the participants in the morning after an overnight fast. The participants were asked to sit in the upright position to ensure minimal venous occlusion time. For the OGTT test, 75 g oral glucose dissolved in 250 to 300 ml water were asked to be consumed in no more than 5 minutes. Plasma samples were separated and retained for analysis of biochemical parameters, including fasting plasma glucose (FPG), fasting plasma insulin (FPI), 2-h post-glucose load (OGTT2h), total cholesterol (TC), triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C), as previously described . Intra- and inter-assay coefficients of variation were <4% for all these assays. Homeostasis model assessment of beta cell function (HOMA-beta) and insulin resistance (HOMA-IR) were employed to assess the status of insulin secretion and insulin action, respectively. HOMA-beta = 20×FPI (µU/ml)/[FPG (mmol/L)-3.5], HOMA-IR = FPG (mmol/L)×FPI (µU/ml)/22.5 .
Plasma HO-1 and C-reactive protein (CRP) concentration were determined by Human HO-1 ELISA Kit (EKS-800, Stressgen/Assay Designs, Ann Arbor, MI, USA) and Human CRP Quantikine ELISA kit (SCRP00, R&D Systems, Minneapolis, MN, USA), respectively. The intra-assay and inter-assay coefficients of variation of these kits have been determined to be <10%.
Statistical analyses were performed using Stata 11.0 (Stata Corp., College Station, TX, USA). Descriptive statistics were calculated for all demographic and clinical characteristics of the study subjects. Comparisons between IGR cases and controls were performed by Chi-square (categorical variables), t test (continuous variables, normal distribution) or Mann-Whitney U test (continuous variables, skewed distribution).
Multivariate logistic regression analysis was used to evaluate the independent association of plasma HO-1 concentration with the likelihood of IGR. Hosmer-Lemeshow goodness-of-fit tests were used to evaluate the appropriate model fit. For calculation of the odds ratios (ORs) for IGR, plasma HO-1 concentrations were categorized in quartiles according to the control group: category 1, <0.56 ng/ml; category 2, 0.56–0.98 ng/ml, category 3, 0.98–1.55 ng/ml and category 4, ≥1.55 ng/ml. Crude and adjusted ORs for IGR were calculated, respectively. To estimate the discriminative value of plasma HO-1 concentrations on IGR, receiver-operating characteristic (ROC) curves were plotted and corresponding areas under the curve (AUC) were compared using a model with known risk factors (Model A, including age, sex, BMI, alcohol consumption, smoking, hypertention and family history of diabetes) and another model with plasma HO-1 concentrations added in (Model B, including Model A Plus HO-1).
All reported P values were 2-sided and P<0.05 was considered to be statistically significant.
Demographic and clinical characteristics of the study subjects
As shown in Table 1, the individuals with IGR, compared to healthy controls, had higher body mass index (BMI), higher prevalence of hypertension and family history of diabetes, higher levels of FPG, OGTT2h, HOMA-IR, TG and CRP, and lower levels of HOMA-beta and HDL-C.
Association between plasma HO-1 levels and odds of IGR
Plasma HO-1 concentration was significantly increased in individuals with IGR compared with controls (Median (interquartile range, IQR) 1.34 (0.81–2.29) ng/ml vs 0.98 (0.56–1.55) ng/ml, respectively; P<0.001) (Figure 1).
Plasma HO-1 concentration was significantly increased in individuals with IGR compared with controls (1.34 (0.81–2.29) ng/ml vs 0.98 (0.56–1.55) ng/ml, respectively; P<0.001).
In the logistic regression analysis, we observed increased ORs for IGR associated with higher level of the plasma HO-1 (Table 2). Individuals in the highest quartile of plasma HO-1 levels had a significantly increased ORs compared with those in the lowest quartile (crude OR 3.45, 95% confidence interval (CI) 2.19–5.42, P for trend <0.001). Adjustment for age, sex and BMI (adjusted OR 3.42, 95% CI 2.11–5.54; P for trend <0.001; Model 1) or further adjustment for smoking, alcohol drinking, hypertension and family history of diabetes (adjusted OR 3.39, 95% CI 2.08–5.54; P for trend <0.001; Model 2) did not alter the results. The trend remained significant even after additional adjustment for lipid profiles (adjusted OR 3.29, 95% CI 2.00–5.43; P for trend <0.001; Model 3) and further C-reactive protein (adjusted OR 3.12, 95% CI 1.89–5.16; P for trend <0.001; Model 4).
ROC curves and corresponding AUCs for IGR using models without or with plasma HO-1 levels
In the ROC curves from the logistic regression models, we first compared the AUCs for IGR using plasma HO-1 levels (continuous variable) with HO-1 categories (categorical variable), and we found that the model using plasma HO-1 levels yielded higher AUC for IGR than plasma HO-1 categories (AUC 0.64 (0.60–0.68) and 0.62 (0.58–0.66), respectively; P = 0.0006 for the difference of the AUCs) (Figure 2). Therefore, in the next step comparison between models without and with plasma HO-1, we chose plasma HO-1 levels in the form of continuous variable.
The AUCs for plasma HO-1 levels and HO-1 categories were 0.64 (0.60–0.68) and 0.62 (0.58–0.66), respectively; P = 0.0006 for the difference of the AUCs. Plasma HO-1 concentrations were categorized in quartiles according to the healthy control group as follows: category 1, <0.56 ng/ml; category 2, 0.56–0.98 ng/ml, category 3, 0.98–1.55 ng/ml and category 4, ≥1.55 ng/ml.
As shown in Figure 3, the AUC for a model with known risk factors (Model A), comprising age, sex, BMI, alcohol consumption, smoking, hypertention and family history of diabetes, was 0.72 (95% CI 0.69–0.76) for IGR. However, when plasma HO-1 concentration was added to the model (Model B, including Model A plus HO-1), the AUC was significantly increased to 0.75 (95% CI 0.71–0.78; P = 0.026 for the difference of the AUCs).
The AUC in a Model A, comprising age, sex, BMI, alcohol consumption, smoking, hypertention and family history of diabetes, was 0.72 (95% CI, 0.69–0.76) and that in Model B (Model A plus plasma HO-1 levels) was 0.75 (95% CI, 0.71–0.78); P = 0.026 for the difference of the AUCs.
The current study indicates that plasma HO-1 concentration is elevated in individuals with IGR in comparison with healthy controls, and it is significantly associated with odds of IGR. The association between plasma HO-1 concentrations and IGR retains rather consistent under adjustment for possible confounding factors including age, sex, BMI, smoking, alcohol drinking, hypertension, family history of diabetes, lipid profiles and CRP, which makes plasma HO-1 more convincing as an emerging independent marker for IGR.
IGR, also referred to pre-diabetes, has been recognized as a metabolic intermediate state between a “normal” state and T2DM , . It should be noted that the IGR state has both progressive and reversible properties. IGR people shows approximately 10-fold higher risk of T2DM , and on the other hand, the onset of T2DM in individuals with IGR can be delayed or prevented through lifestyle modifications , . Therefore, it is crucial to elucidate the underlying mechanisms of IGR and to develop biomarkers to understand the role of corresponding mechanisms in human.
Under high glucose exposure, HO-1 gene expression and enzyme activities in the islets are elevated remarkably in parallel with hyperglycemia-induced intracellular peroxide levels , , prior to the elevation of classical antioxidant enzymes (e.g., superoxide dismutase, catalase and glutathione peroxidase) . In addition, HO-1 mediates the anti-inflammatory effect of interleukin-10 through a p38 mitogen-activated protein kinase-dependent pathway .
Recently, it has been found that HO-1 is present and detectable in serum or plasma samples and serves as a systemic stress marker , . Elevated circulating HO-1 levels are subsequently found in several oxidative stress-related illness conditions, such as in chronic silicosis , T2DM , acute myocardial infarction , coronary microvascular dysfunction , Parkinson's disease , and critically ill patients . Similar to our previous report , we found that plasma HO-1 concentrations were significantly correlated with fasting plasma glucose, 2 hour OGTT glucose, HOMA-beta and HOMA-IR in this population. Taken together with our previous study , the study shows an association that could suggest that HO-1 is responsive to high blood glucose, even if under moderate hyperglycemia in the form of IGR. The current study also suggests that plasma HO-1 concentration can significantly improve the discriminative value for IGR. If the utility of HO-1 be confirmed in prospective cohort studies, it might be incorporated into established panel of biomarkers  to help further improve the predictive value for IGR and T2DM.
There are several limitations to this study. First, the current case-control study design could not allow examining the causal relationship between plasma HO-1 and IGR, which remains to be confirmed in further prospective cohort studies. We also cannot directly evaluate the predictive value for IGR, thus we only evaluate the discriminative value instead. Second, we did not have information on diet and physical activity among the participants, while it is possible that individuals with IGR have a different dietary and exercise habits compared to controls. Whether such difference confounds our results remains unknown. Third, since it has been demonstrated that changes in 2-h postload glucose develops years prior to worsening in fasting glucose , IFG and IGT might represent not only different types of glucose abnormality, but also different stages along the same line of abnormality. However, we did not perform a separate analysis for IFG group and IGT group, because there were only 21 IFG subjects (8%) in our IGR cases group. Whether there is a significant difference in association between HO-1-IFG and HO-1-IGT merits further investigation. Fourth, diabetic comorbidities may occur in a small portion of patients with prediabetes. Although we excluded those with known cardiovascular disease, it was difficult to eliminate potential bias because elevated circulating HO-1 levels may be a result of diabetic comorbidities. Fifth, all participants in this study were of Chinese Han ethnicity, which minimizes the confounding effects by ethnic background. Whether these results can be generalized to other populations need to be studied further.
In conclusion, elevated plasma HO-1 concentration is significantly associated with increased ORs for IGR. However, its clinical utility should be validated in further studies, especially in prospective cohort studies.
The authors thank all the participants for their support; Wenbo Jia, Fangfang Song, Yafei Hu, Jie Lin and Rui Wang for contributions in data collecting.
Conceived and designed the experiments: WB FBH LL. Performed the experiments: WB SR MZ XY YZ XX WY DW PY. Analyzed the data: WB SR PY FBH LL. Contributed reagents/materials/analysis tools: WB MZ XY PY. Wrote the paper: WB LL.
- 1. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, et al. (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. JAMA 285: 2109–2113.
- 2. Unwin N, Shaw J, Zimmet P, Alberti KG (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708–723.
- 3. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52: 1–8.
- 4. Song F, Jia W, Yao Y, Hu Y, Lei L, et al. (2007) Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed Type 2 diabetes. Clin Sci (Lond) 112: 599–606.
- 5. Platt JL, Nath KA (1998) Heme oxygenase: protective gene or Trojan horse. Nat Med 4: 1364–1365.
- 6. Ryter SW, Alam J, Choi AM (2006) Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev 86: 583–650.
- 7. Morse D, Choi AM (2002) Heme oxygenase-1: the “emerging molecule” has arrived. Am J Respir Cell Mol Biol 27: 8–16.
- 8. Abraham NG, Kappas A (2008) Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev 60: 79–127.
- 9. Bao W, Song F, Li X, Rong S, Yang W, et al. (2010) Plasma heme oxygenase-1 concentration is elevated in individuals with type 2 diabetes mellitus. PLoS One 5: e12371.
- 10. Caselli C, Cabiati M, Prescimone T, Del Ry S, Pardini S, et al. (2011) Heme oxygenase-1 in patients with idiopathic left ventricular and coronary microvascular dysfunction: Relationship with diabetes/insulin resistance. European Heart Journal 32: 1092.
- 11. Okuhara K, Kisaka T, Ozono R, Kurisu S, Inoue I, et al. (2010) Change in bilirubin level following acute myocardial infarction is an index for heme oxygenase activation. South Med J 103: 876–881.
- 12. Sato T, Takeno M, Honma K, Yamauchi H, Saito Y, et al. (2006) Heme oxygenase-1, a potential biomarker of chronic silicosis, attenuates silica-induced lung injury. Am J Respir Crit Care Med 174: 906–914.
- 13. Mateo I, Infante J, Sanchez-Juan P, Garcia-Gorostiaga I, Rodriguez-Rodriguez E, et al. (2010) Serum heme oxygenase-1 levels are increased in Parkinson's disease but not in Alzheimer's disease. Acta Neurol Scand 121: 136–138.
- 14. Saukkonen K, Lakkisto P, Kaunisto MA, Varpula M, Voipio-Pulkki LM, et al. (2010) Heme oxygenase 1 polymorphisms and plasma concentrations in critically ill patients. Shock 34: 558–564.
- 15. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553.
- 16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.
- 17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26: Suppl 1S5–20.
- 18. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343–1350.
- 19. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393–403.
- 20. Jonas JC, Guiot Y, Rahier J, Henquin JC (2003) Haeme-oxygenase 1 expression in rat pancreatic beta cells is stimulated by supraphysiological glucose concentrations and by cyclic AMP. Diabetologia 46: 1234–1244.
- 21. Won KC, Moon JS, Eun MJ, Yoon JS, Chun KA, et al. (2006) A protective role for heme oxygenase-1 in INS-1 cells and rat islets that are exposed to high glucose conditions. J Korean Med Sci 21: 418–424.
- 22. Tiedge M, Lortz S, Drinkgern J, Lenzen S (1997) Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 46: 1733–1742.
- 23. Lee TS, Chau LY (2002) Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med 8: 240–246.
- 24. Schipper HM, Chertkow H, Mehindate K, Frankel D, Melmed C, et al. (2000) Evaluation of heme oxygenase-1 as a systemic biological marker of sporadic AD. Neurology 54: 1297–1304.
- 25. Kolberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, et al. (2009) Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes Care 32: 1207–1212.
- 26. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, et al. (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373: 2215–2221.